242,787 Shares in Merit Medical Systems, Inc. $MMSI Acquired by J. Goldman & Co LP

J. Goldman & Co LP acquired a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 242,787 shares of the medical instruments supplier’s stock, valued at approximately $16,835,000. J. Goldman & Co LP owned about 0.41% of Merit Medical Systems as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new stake in Merit Medical Systems in the 4th quarter worth $25,000. Kilter Group LLC bought a new position in shares of Merit Medical Systems during the second quarter valued at about $25,000. Torren Management LLC bought a new position in shares of Merit Medical Systems during the fourth quarter valued at about $38,000. Covestor Ltd boosted its holdings in shares of Merit Medical Systems by 252.6% during the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Merit Medical Systems in the third quarter worth about $42,000. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems News Roundup

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. Estimates were also raised for Q2 2027, Q3 2027, Q1 2028 and Q2 2028, suggesting improving expectations for Merit Medical’s earnings trajectory.
• Positive Sentiment: Growth initiatives are strengthening the investment case: New product launches, acquisitions and a broader portfolio of therapeutic medical products are supporting stronger growth and improving the company’s business mix. Recent quarterly results also showed revenue growth and an EPS beat, while the company raised its 2026 outlook. Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
• Neutral Sentiment: Short-interest data provides no meaningful signal: Reported short interest was zero shares both on August 10 and August 25, with a zero-day days-to-cover ratio. The reported “increase” is mathematically invalid, so the data does not indicate either meaningful short covering or rising bearish positioning.
• Negative Sentiment: Valuation and risk remain concerns: MMSI’s recent rally has left the stock trading at a premium valuation, increasing the need for continued earnings delivery. Analysts also cited tariff exposure and execution risks related to launches and acquisitions as potential headwinds. Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Robert W. Baird set a $98.00 price target on Merit Medical Systems in a report on Friday, July 31st. JPMorgan Chase & Co. boosted their target price on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Bank of America upped their target price on Merit Medical Systems from $92.00 to $97.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Piper Sandler lifted their price target on shares of Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Needham & Company LLC boosted their price objective on shares of Merit Medical Systems from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Merit Medical Systems has a consensus rating of “Moderate Buy” and an average price target of $100.00.

Merit Medical Systems Stock Performance

Merit Medical Systems stock opened at $91.09 on Wednesday. Merit Medical Systems, Inc. has a fifty-two week low of $59.74 and a fifty-two week high of $94.75. The stock’s 50 day simple moving average is $78.35 and its two-hundred day simple moving average is $72.66. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of 37.64, a PEG ratio of 2.25 and a beta of 0.49.

Merit Medical Systems (NASDAQ:MMSI) last announced its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The firm had revenue of $418.84 million during the quarter, compared to analyst estimates of $405.25 million. During the same quarter in the prior year, the company earned $1.01 EPS. The business’s revenue was up 9.5% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, analysts expect that Merit Medical Systems, Inc. will post 3.84 earnings per share for the current fiscal year.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.